[go: up one dir, main page]

WO1998009989A1 - Emploi de peptides du type muramylpeptides pour le traitement de troubles de myelosuppression ou d'autres etats affectant l'immunite - Google Patents

Emploi de peptides du type muramylpeptides pour le traitement de troubles de myelosuppression ou d'autres etats affectant l'immunite Download PDF

Info

Publication number
WO1998009989A1
WO1998009989A1 PCT/GB1997/002422 GB9702422W WO9809989A1 WO 1998009989 A1 WO1998009989 A1 WO 1998009989A1 GB 9702422 W GB9702422 W GB 9702422W WO 9809989 A1 WO9809989 A1 WO 9809989A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetyl
glucosaminyl
gmdp
alanyl
acetylmuramyl
Prior art date
Application number
PCT/GB1997/002422
Other languages
English (en)
Inventor
Philip Ledger
Roger Aston
Original Assignee
Peptech (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech (Uk) Limited filed Critical Peptech (Uk) Limited
Priority to AU43073/97A priority Critical patent/AU4307397A/en
Priority to CA002265890A priority patent/CA2265890A1/fr
Publication of WO1998009989A1 publication Critical patent/WO1998009989A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the use of Muramyl peptides in the preparation of an agent for the alleviation of myelosuppression.
  • it relates to such use in the preparation of an agent for alleviating myelosuppression following treatment of cancer patients by radiation or chemotherapy.
  • the muramyl peptides are a class of glycopeptide compounds which in nature constitute part of bacterial cell walls (Ellouz et al , Biochem Biophys Res Comm, 59:1317-1325, (1974)). This term has also come to include synthetic variants of naturally occurring forms. Muramyl peptides were discovered by virtue of their ability to act as adjuvants to injected vaccines (Adam, Synthetic adjuvants, In: Modern concepts in Immunology, Vol 1, (1985)) .
  • N-acetylmuramyl -L-alanyl-D-isoglutamine MDP
  • Another class of muramyl peptide contains a disaccharide, namely N-acetylglucosaminyl -N-acetylmuramic acid.
  • the simplest of these compounds is N-acetylglucosaminyl-N- acetylmuramyl-L-alanyl-D-isoglutamine, abbreviated as GMDP .
  • GMDP N-acetylglucosaminyl-N- acetylmuramyl-L-alanyl-D-isoglutamine
  • GMDP has properties distinct from MDP. For example, GMDP is less pyrogenic (fever inducing) than MDP, and in some circumstances has more distinct anti-inflammatory properties (Adeleye et al , (1994), supra) .
  • chemotherapeutic drugs has greatly increased the medical profession's ability to successfully treat numerous types of cancer.
  • irradiation of the human body is used for certain cancers.
  • the principal of these treatments is to kill rapidly dividing cells, such as the rapidly dividing cells of a tumour.
  • certain healthy cells of the body also divide rapidly, and their damage by the cancer treatment methods results in unwanted side effects of the treatment.
  • skin and hair bulb cells, and the cells lining the gut are rapidly dividing, and disturbances in these tissues are well known in patients undergoing cancer therapy.
  • damage caused to so-called hematopoietic ("blood forming") tissues the consequence of which is a reduction in the number of circulating cells of the immune system. While this is not harmful per se, the reduced immune function renders these patients more susceptible to life threatening infections.
  • myelosuppressive side-effect is evidenced by the fact that repeated cycles of anti-cancer treatment are often reduced in intensity or delayed in time, in order for immune function to become restored to an acceptable level.
  • Therapeutic agents have therefore been developed which can counteract the myelosuppressed state.
  • the best known and currently most widely used of these are the so-called "colony stimulating factors", which cause precursors of the immune cells to differentiate and multiply, and therefore replenish the cells killed by the radiation or chemotherapy.
  • These factors are proteinaceous, expensive to produce, and have to be administered by repeat injection or infusion (Gabrilove et al , New England J Med, 318:1414-22, (1988)).
  • CSF colony stimulating factors
  • G-CSF granulocyte - CSF
  • mice rendered neutropenic with cyclophosphamide and subsequently treated with GMDP did not increase neutrophil numbers above the CYA controls.
  • GMDP did not increase neutrophil numbers above the CYA controls.
  • the effect on neutrophil number was lower, when these same animals were challenged with a potentially lethal dose of the micro-organism Candida, GMDP gave a very effective protection against lethality, compared to the high mortality seen in animals receiving CYA alone.
  • neutrophil induction alone is not a good indicator of overall efficacy against "neutropenia", in which the most important feature is protection from the clinical consequences of immune suppression, not just the cell count per se .
  • "immunostimulation” is not a single activity, or G-CSF would have been more effective than GMDP. Therefore the knowledge that GMDP is an immunostimulator is not sufficient to predict that it would be so effective at treating chemotherapy- induced neutropenic immunosuppression.
  • Vast numbers of i munostimulators have been identified over the years however only a very small handful have found utility in the market place. The correct balance of immune cell activation appears to be critical for the identification of drugs with clinical utility.
  • Example 2 we have shown that in a mouse model, most surprisingly, a strong effect on neutrophils is seen after oral administration of GMDP as well as after injection of GMDP. The significance of this observation needs to be considered in the light of human clinical data. Thus, in human clinical Phase I studies (example
  • GMDP was administered as oral tablets. Doses of up to 50 gm were given with no significant induction of fever or side effects (Example 4) . From animal studies, it is known that when administered by the oral route typically about 10% of GMDP enters the systemic circulation. However, the human oral dose cited above (50mg) , is 200 times greater than the 250 micrograms which causes fever by injection. This absence of side effects from oral administration is therefore most surprising, meaning that it has the potential to provide a useful treatment for neutropenia, particularly in situations where patients are already suffering from infections i.e. febrile neutropenia.
  • GMDP is effective at protecting from infection in general, and this has been disclosed in Khaitov et al , (In Immunology of Infections, Ed Masihi pp205-215 Pub Dekker, (1994)), infection occurring during the i mm u n o s upp r e s s e d post-chemotherapeutic state can take several forms, and the highest occurrence is of pulmonary infection or pneumonia. To our surprise, we have found in clinical trials (Example 7) that GMDP is particularly effective at preventing such pulmonary infections. The accumulation of this evidence is that (1) GMDP shows a surprising degree of efficacy in the treatment of functional consequences of neutropenia (i.e.
  • Muramyl peptides show a diverse range of properties and it is impossible to predict in which clinical circumstance a particular biological property can be exploited as a useful treatment. This fact is particularly highlighted by the observation that although MDPs were discovered over 20 years ago, to this day they have only found limited clinical utility.
  • the specific use of GMDP as an effective method for the treatment of neutropenia therefore represents a non-obvious and novel invention over the existing state of the art .
  • the present invention provides the use of a muramyl peptide compound of general formula
  • R represents a residue of an amino acid or a linear peptide built of from 2 to 6 amino acid residues , at least one of the residues being optionally substituted with a lipophilic group;
  • n 1 or 2;
  • the agent in the preparation of an agent for the treatment of myelosuppressed or otherwise immunocompromised states, wherein the agent is adapted for oral administration and comprises 0.5-50mg of the muramyl peptide.
  • the term "alleviation of myelosuppression” will be clear to the skilled man. In general it will mean that the agent comprising the muramyl peptide compound will be capable of restoring immune function in patients who will potentially be myelocompromised, for instance following radiation treatment or chemotherapy. Moreover, this should be associated with an increased resistance to the clinical consequence of myelosuppression, ie infection.
  • R preferably represents a mono-, di- or tri -peptide.
  • the proximal peptide residue (or the only peptide residue, if there is only one) is preferably that of an L-amino acid. Examples include: L-alanyl L-tryptophanyl
  • L-alanyl is preferred, as is L-threonyl.
  • the peptide R correspond to the peptide in prototype MDP (L-Ala-D- isoGln) .
  • R may represent L-Ala-D-Glu.
  • n 1
  • the next amino acid from the proximal end of the peptide is preferably of the D-configuration. It is preferably acidic and may be D-glutamic or D-aspartic acid or a mono-, di- or mixed C j ⁇ C ⁇ (preferably C ⁇ -Cg) alkyl ester, amide or C x -C 4 alkyl amide thereof.
  • C j ⁇ C ⁇ preferably C ⁇ -Cg alkyl ester, amide or C x -C 4 alkyl amide thereof.
  • the expression “mixed” is illustrated when one carboxyl group is amidated and the other esterified. D-isoglutamine and D- glutamate are preferred.
  • a third amino acid residue from the proximal end of the chain is preferably of the L- configuration, as indicated above in relation to the proximal amino acid residue.
  • L-alanyl and L-lysyl are preferred.
  • the amino acid residue or linear peptide is optionally substituted with at least one lipophilic group.
  • the lipophilic group may be a C 10 - C 22 acyl group such as stearoyl or a di- (C 10 -C 22 acyl) -srz-glycero-3 ' -hydroxy- phospheryloxy-group wherein for example each of the C 10 - C 22 acyl groups can be a palmitoyl group.
  • the lipophilic group may alternatively (or in addition, as more than one substitution may be present) be a C, -C 10 ester group, such as a C 2 -C 6 ester group: a butyl ester is an example.
  • GMDP N-acetyl-D-glucosaminyl- (/31-4) -N-acetylmuramyl-L-alanyl- D-isoglutamine
  • formula I N-acetyl-D-glucosaminyl- (61-4) -N-acetylmuramyl-L-alanyl - D-glutamic acid (GMDP-A) which has the structure:
  • GMDP-LL N-acetyl-D-glucosaminyl- (31-4) -N acetylmuramyl -L-alanyl L-isoglutamine
  • N-acetyl-D-glucosaminyl- (,61-4) -N acetylmuramyl -L-alanyl - D-glutamine n-butyl ester (GMDP-OBu) which has the structure :
  • Lys (St) which has the structure:
  • N°- [N-Acetyl-D-glucosaminyl- (61- -4) -N-acetyl-muramyl -L- alanyl- ⁇ -D-glutamyl] -N £ -stearoyl-L-lysine which has the structure :
  • N-Acetyl-D-glucosaminyl- (61--4) -N- acetylmuramyl -L-alanyl - D-glutamic acid dibenzyl ester which has the structure:
  • N-Acetyl-D-glucosaminyl- (61--4) -N-acetylmuramyl-N-methyl- L-alanyl-D-isoglutamine which has the structure:
  • N-Acetyl-D-glucosaminyl- (61- -4) -N-acetylmuramyl-L alanyl-D-isoglutamine 1-adamantyl ester which has the structure :
  • N e [N-Acetyl-D-glucosaminyl- (61--4) -N-acetyl-muramyl-L- alanyl- ⁇ -D-isoglutaminyl] -L- lysyl-L- hist idyl -L-glycine amide which has the structure :
  • N-Acetyl-D-glucosaminyl- ( 1--4) -N-acetylmuramyl-L-alanyl- D-isoglutaminyl-L-glutamyl-L-tryptophan which has the structure :
  • N-Acetyl-D-glucosaminyl- (61--4) -N-acetylmuramyl -L-alanyl - D-isoglutaminyl- e -aminohexanoyl-L-glutamyl-L-tryptophan which has the structure:
  • N-acetylmuramyl-L-threonyl-D-isoglutamine which has the structure :
  • N-acetylmuramyl-L-alanyl-D-glutamine n-butyl ester which has the structure:
  • the most preferred compound is GMDP followed by GMDP-A, and murabutide.
  • Glucosaminyl-muramyl dipeptides within the scope of general formula I can be prepared relatively cheaply and in reasonably large quantities by the process disclosed in US-A-4395399.
  • the preparation disclosed is based on the extraction and purification of the disaccharide component from the bacterium Micrococcus lysodecticus and its subsequent chemical linkage to a dipeptide synthesised for example by conventional peptide chemistry.
  • the disaccharide may equally well be chemically synthesised using standard sugar chemistry.
  • the agent will comprise l-5mg of the muramyl peptide compound and most preferably 5mg .
  • the agent can in fact comprise one or more muramyl peptide compounds.
  • the agent could also comprise one or more other active ingredients capable of alleviating immunosuppression.
  • composition of a tablet suitable for oral administration could be as follows:
  • Muramyl peptide eg GMDP 5mg; lactose 145 mg; maize starch 84 mg; polyvidone 5.5 mg; magnesium stearate 2.5 mg; talc 7.6 g;
  • agent comprising the muramyl peptide compound could be in the form of a syrup or solution which would also be suitable for oral administration.
  • GMDP has a relatively low bioavailability, (measured at 10% in the rat and the dog) . It is possible that GMDP could be formulated into more sophisticated oral delivery compositions that gave improved bioavailability. If this were done, the absolute dose of GMDP necessary to have an anti -myelosuppressive effect would be different. Thus, for example, if GMDP bioavailability were increased by, for example, twofold, the preferred dose of GMDP would be reduced by half.
  • the present invention provides a method for the alleviation of myelosuppression in a subject which comprises administering to the subject 0.5- 50mg of a muramyl peptide compound.
  • the method comprises administering 1-5, and most preferably 5mg of a muramyl peptide compound as defined herein to the subject.
  • the muramyl peptide compound is GMDP.
  • FIGURE 1 shows the results of administration of
  • mice which have been rendered immunosuppressed by treatment with cyclophosphamide;
  • FIGURE 2 shows the effect on neutrophil count of varying doses of GMDP on mice which had been treated with cyclophosphamide .
  • mice were rendered immunosuppressed by treatment with cyclophosphamide (3 successive days at 30mg/kg) . Following that, mice were challenged with Candida (4.8 x 10 6 cfu/mouse) and then three successive daily treatments with GMDP or G-CSF. Mortality was scored, and neutrophil counts.
  • the CYA treatment effectively induced severe neutropenia in the mice (day 0 levels compared to vehicle control) .
  • GMDP did not increase neutrophils numbers above the spontaneous increase in cyclophosphamide control .
  • Example 2 Five groups of 35 mice each received a dose of the cancer chemotherapeutic agent cyclophosphamide which was known to be sufficient to induce severe leukopenia (reduction in numbers of white cells) . The groups then received different treatments. These were: Group 1 - no treatment (controls)
  • mice from each group were sacrificed, and blood taken. A complete blood count was performed to enumerate the number and proportions of the cell types present. The results are shown in Figure 2 It was found that GMDP administered both by injection and orally were capable of boosting the number of white cells in the blood. Surprisingly the 0.025 mg/kg oral dose was as effective as the injected dose.
  • Example 3 Healthy volunteers were given sterile, endotoxin-free injections of GMDP dissolved in saline. Blood samples were taken at intervals and temperature was monitored.
  • Healthy volunteers were given tablets of GMDP with a glass of water as part of a Phase I safety trial. In addition to monitoring general status, blood biochemistry, temperature was taken at regular intervals over 24 hours.
  • GMDP GMDP (2 mg/day) for 6 days immediately following a treatment course with cancer chemotherapy (mitomycin, methotrexate, mitoxanthrone) . Blood counts were performed periodically. It was found that GMDP was able to reduce the duration and severity of the depression of white blood cells induced by chemotherapy.
  • mice received various combinations of treatment with cyclophosphamide (200mg/kg) to induce myelosuppression, and GMDP (lOmg/kg, subcutaneous) according to the treatment schedule shown in the table below. All mice were challenged with 7 x 10 5 organisms of E . coli on day 5 and sacrificed on day 6, at which time the number of E. coli organisms present in the liver was determined.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur l'emploi de composés de peptides de type muramyle pour la préparation d'un agent atténuant l'immunosuppression.
PCT/GB1997/002422 1996-09-06 1997-09-08 Emploi de peptides du type muramylpeptides pour le traitement de troubles de myelosuppression ou d'autres etats affectant l'immunite WO1998009989A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU43073/97A AU4307397A (en) 1996-09-06 1997-09-08 The use of muramylpeptides in the treatment of myelosuppressed or otherwise immunocompromised states
CA002265890A CA2265890A1 (fr) 1996-09-06 1997-09-08 Emploi de peptides du type muramylpeptides pour le traitement de troubles de myelosuppression ou d'autres etats affectant l'immunite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9618673.9 1996-09-06
GBGB9618673.9A GB9618673D0 (en) 1996-09-06 1996-09-06 The use of muramyl peptides

Publications (1)

Publication Number Publication Date
WO1998009989A1 true WO1998009989A1 (fr) 1998-03-12

Family

ID=10799557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002422 WO1998009989A1 (fr) 1996-09-06 1997-09-08 Emploi de peptides du type muramylpeptides pour le traitement de troubles de myelosuppression ou d'autres etats affectant l'immunite

Country Status (5)

Country Link
AU (1) AU4307397A (fr)
CA (1) CA2265890A1 (fr)
GB (1) GB9618673D0 (fr)
WO (1) WO1998009989A1 (fr)
ZA (1) ZA978027B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1617860A4 (fr) * 2003-04-09 2006-12-13 Vladimir Slesarev Peptides de glucosaminemuramyl biodegradables pour modulation de l'apoptose
WO2016167682A1 (fr) * 2015-04-16 2016-10-20 Закрытое акционерное общество "ПЕПТЕК" Traitement à combinaison spécifique des tumeurs malignes par un agent cytostatique et son modificateur
US11859021B2 (en) 2021-03-19 2024-01-02 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
US12377054B2 (en) 2016-04-29 2025-08-05 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031533A1 (fr) * 1995-04-07 1996-10-10 Vacsyn S.A. Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et composition les contenant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031533A1 (fr) * 1995-04-07 1996-10-10 Vacsyn S.A. Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et composition les contenant

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
File Medline, abstract no. 82112503 *
File Medline, abstract no. 92288096 *
File Medline, abstract no. 93184410, 1993 *
J J KILLION ET AL.: "Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents", ONCOLOGY RESEARCH, vol. 4, no. 10, 1992, pages 413 - 418 *
K FURUSE & A SAKUMA: "Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., vol. 39, no. 8, August 1989 (1989-08-01), AULENDORF DE, pages 915 - 917, XP002053351 *
K MATSUMOTO ET AL.: "Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N-alpha-muramyl dipeptide-N-epsilon-stearoyllysine", INFECTION AND IMMUNITY., vol. 39, no. 3, March 1983 (1983-03-01), WASHINGTON US, pages 1029 - 1040, XP002053350 *
R B GALLAND ET AL.: "Nonspecific enhancement of resistance to local bacterial infection in starved mice", ARCHIVES OF SURGERY, vol. 117, no. 2, February 1982 (1982-02-01), pages 161 - 164 *
T O'REILLY & O ZAK: "Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators", CLINICAL INFECTIOUS DISEASES, vol. 14, no. 5, May 1992 (1992-05-01), pages 1100 - 1109 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1617860A4 (fr) * 2003-04-09 2006-12-13 Vladimir Slesarev Peptides de glucosaminemuramyl biodegradables pour modulation de l'apoptose
WO2016167682A1 (fr) * 2015-04-16 2016-10-20 Закрытое акционерное общество "ПЕПТЕК" Traitement à combinaison spécifique des tumeurs malignes par un agent cytostatique et son modificateur
EA031099B1 (ru) * 2015-04-16 2018-11-30 Акционерное Общество "Пептек" Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
US12377054B2 (en) 2016-04-29 2025-08-05 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US11859021B2 (en) 2021-03-19 2024-01-02 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use

Also Published As

Publication number Publication date
GB9618673D0 (en) 1996-10-16
CA2265890A1 (fr) 1998-03-12
AU4307397A (en) 1998-03-26
ZA978027B (en) 1999-03-05

Similar Documents

Publication Publication Date Title
Parant Biologic properties of a new synthetic adjuvant, muramyl dipeptide (MDP)
AU666890B2 (en) Muramyl compounds for treatment of septic shock
Sone et al. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.
JPH02502826A (ja) 免疫欠損状態の治療のための医薬製剤
SK2697A3 (en) Use of muramyl peptide compounds and pharmaceutical composition
Nishioka et al. Tuftsin: an immunomodulating peptide hormone and its clinical potential as a natural biological response modifier
US4390528A (en) Tuftsinyl-tuftsin
WO1998009989A1 (fr) Emploi de peptides du type muramylpeptides pour le traitement de troubles de myelosuppression ou d'autres etats affectant l'immunite
US6103699A (en) Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
WO1985004808A1 (fr) Produit pharmaceutique ayant une activite antitumorale; utilisation du produit pharmaceutique ou de compositions pharmaceutiques dans une therapie antitumorale
CA2122024A1 (fr) Compositions pharmaceutiques a base de polypeptides renfermant de la lysine et methodes d'utilisation
Parant Biologic properties of a new synthetic adjuvant, muramyl dipeptide (MDP)
Cottney et al. Modulation of the immune system in the mouse. 2. Drug administration following antigen sensitization
WO1997048725A1 (fr) Nouveaux peptides pour la prevention et le traitement d'infections
WO1997043308A1 (fr) Derives lipophiles de muramylpeptides pour le traitement des infections retrovirales et liberation de chemokines
AU2018205885A1 (en) Peptides for treating Sjogren's syndrome
US20030166539A1 (en) Compositions and methods of use for a bombesin peptide
US6346514B1 (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof
WO1993013791A1 (fr) Utilisation de peptides de muramyl pour stimuler la production animale
ten Hagen et al. Immunomodulation With MDP Analogues and IFN-y in Experimental Gram-negative Septicemia: Emphasis on the use of liposomes as drug carriers.
EP0621789A1 (fr) Compositions pentapeptidiques pharmaceutiques et leurs procedes d'utilisation
Adam¹ et al. Muramyl peptides
WO1985004807A1 (fr) Produit pharmaceutique ayant une activite antitumorale; utilisation du produit pharmaceutique ou de compositions pharmaceutiques dans une therapie antitumorale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2265890

Country of ref document: CA

Ref country code: CA

Ref document number: 2265890

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09254423

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998509201

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase